Liu Yahui, Huang Chunrong, Du Juan, Lan Gelei, Du Xueqing, Sun Yidan, Shi Guochao
Department of Respiratory and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Institute of Respiratory Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Front Med (Lausanne). 2022 Sep 6;9:915159. doi: 10.3389/fmed.2022.915159. eCollection 2022.
Testosterone deficiency is common in chronic obstructive pulmonary disease (COPD) patients. There has been a growing interest in the potential use of anabolic-androgenic steroids (AASs) in patients with COPD recently. However, whether AASs could improve their clinical outcomes remains unknown.
In order to explore the efficacy of AASs in patients with COPD, systematic search of MEDLINE, Embase, the Cochrane Library and ClinicalTrials.gov for randomized controlled trials (RCTs) of AASs for COPD published before March 17, 2022 was performed.
Data were extracted from 8 articles involving 520 participants. The median number of participants per study was 39.5 and the mean follow up was 14.2 weeks. As compared to the control group, AASs therapy could significantly improve body weight (weighted mean difference (WMD), 1.38 kg; 95% CI, 0.79 to 1.97 kg), fat-free mass (WMD, 1.56 kg; 95% CI, 0.94 to 2.18 kg) and peak workload (WMD, 6.89W; 95% CI, 3.97 to 9.81W) of COPD patients, but no improvements in spirometry indicators and six-minute walking distances (WMD, 16.88 m; 95%, -3.27 to 37.04 m). Based on the available research data, it is uncertain whether AASs treatment could improve the quality of life of COPD patients.
Limited published evidence indicates that AASs therapy provides clinical benefits in patients with COPD. However, longer and larger studies are needed to better clarify the efficacy of AASs and draw final conclusions.
睾酮缺乏在慢性阻塞性肺疾病（COPD）患者中很常见。近来，人们对合成代谢雄激素类固醇（AASs）在COPD患者中的潜在应用兴趣日益浓厚。然而，AASs是否能改善其临床结局仍不清楚。
为了探究AASs对COPD患者的疗效，我们对MEDLINE、Embase、Cochrane图书馆和ClinicalTrials.gov进行了系统检索，以查找2022年3月17日前发表的关于AASs用于COPD的随机对照试验（RCTs）。
从8篇文章中提取了数据，涉及520名参与者。每项研究的参与者中位数为39.5，平均随访时间为14.2周。与对照组相比，AASs治疗可显著改善COPD患者的体重（加权平均差（WMD），1.38 kg；95%可信区间（CI），0.79至1.97 kg）、去脂体重（WMD，1.56 kg；95%CI，0.94至2.18 kg）和峰值工作量（WMD，6.89W；95%CI，3.97至9.81W），但肺活量测定指标和6分钟步行距离无改善（WMD，16.88 m；95%，-3.27至37.04 m）。根据现有研究数据，尚不确定AASs治疗能否改善COPD患者的生活质量。
有限的已发表证据表明，AASs治疗对COPD患者有临床益处。然而，需要开展更大规模、更长时间的研究，以更好地阐明AASs的疗效并得出最终结论。
